A repurposed drug may help target one of depression’s hardest symptoms
Researchers in Sweden say pramipexole, a drug long used to treat Parkinson’s disease, showed promise as an add-on therapy for patients with treatment-resistant depression marked by anhedonia, the blunting of pleasure, motivation, and interest that many standard antidepressants struggle to relieve.
The study, published in Nature Medicine, focused on a subgroup of depression patients whose symptoms center not only on low mood but also on a reduced capacity to feel reward. That distinction is important because anhedonia is often one of the most debilitating features of depressive illness and one of the symptoms least reliably improved by existing treatments.
According to the supplied source text, all participants had marked anhedonia and continued their existing medication while receiving either pramipexole or placebo over nine weeks. Patients treated with pramipexole showed more pronounced improvement than the placebo group, and among those who chose to remain on treatment, the benefit persisted through a six-month follow-up period.
Why this result stands out
Depression is not a single uniform condition, yet treatment often proceeds as though it were. Many antidepressants can reduce sadness, anxiety, or agitation while leaving motivation and reward processing only partly improved. That mismatch helps explain why some patients are labeled treatment-resistant even after trying multiple therapies.
The Swedish team specifically targeted anhedonia, rather than depression in the broadest sense, and that choice gives the study practical significance. If clinicians can better match therapies to symptom profiles, treatment may become more precise and more effective for groups that have not done well with standard options.
Pramipexole is also an example of drug repurposing: using an already approved medicine for a new indication. That can shorten the path from research finding to clinical use because the medication’s basic safety profile is already better understood than that of a wholly novel compound.
The brain-imaging link
The researchers did not stop at symptom questionnaires. The supplied source text says they used 7 Tesla functional MRI to investigate possible biological mechanisms behind the improvement and found effects on reward-related ventral striatal activation.
That matters because it connects clinical change to a plausible neural pathway. Anhedonia is closely tied to the brain’s reward circuitry, and evidence that the drug influences activity in that system helps support the interpretation that the benefits are not merely incidental.
It also strengthens the broader move toward biologically informed psychiatry. Mental-health treatment has often advanced through trial and error, with patients cycling through medications based on population averages. Studies that combine symptom targeting with imaging-based mechanisms offer a more grounded way to think about who may benefit and why.
What pramipexole is and why it may fit
Pramipexole has been used for Parkinson’s disease, where dopamine-related pathways are central to symptom control. While the supplied text does not present a full mechanistic argument, the relevance to anhedonia is intuitive: motivation, reward sensitivity, and goal-directed behavior are all deeply connected to dopaminergic signaling.
That does not mean the drug will be appropriate for all patients with depression. The study is framed as evidence of promise in a defined subgroup, particularly those with treatment-resistant depression and marked anhedonia. Precision in that framing is important because psychiatric medications can have different risk-benefit profiles across patients and contexts.
The findings therefore add to a growing effort to split depression into more clinically meaningful dimensions rather than treating it as a monolith.
What clinicians and patients should take from it
The result is encouraging because it targets a domain of suffering that many patients describe as especially isolating: the disappearance of motivation, interest, and reward. These symptoms can persist even when some mood measures improve, and they can severely limit a person’s ability to work, relate to others, and engage in daily life.
At the same time, this is not yet a blanket treatment recommendation. The supplied source text describes a controlled trial and follow-up findings, but broader replication, patient selection criteria, and longer-term evaluation will still matter. Questions remain about which patients benefit most, how durable the effect is, and how tolerability compares across clinical settings.
Even so, the study gives psychiatry something valuable: a credible signal that one difficult symptom cluster may respond to a repurposed medicine with a biologically plausible mechanism.
A broader shift in depression treatment
The study also reflects a wider change in mental-health research. Instead of asking only whether a drug works for “depression,” investigators are increasingly asking which component of depression it affects. That approach is more likely to produce meaningful advances, because the condition includes multiple overlapping symptom dimensions that may not share the same biology.
If pramipexole continues to perform well in future studies, it could become part of a more tailored treatment strategy for patients whose depression is dominated by anhedonia. That would be a significant development in a field where many approved treatments still leave core impairments untouched.
For now, the main takeaway is careful optimism. An established Parkinson’s drug appears to have helped some patients with a stubborn and disabling form of depression, and it did so in a way that aligns with what brain imaging suggests about reward dysfunction. In psychiatric drug development, that combination is worth close attention.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
